XML 44 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]  
Schedule of stock options activity
   Number of options   Weighted average exercise price  

Weighted average remaining contractual
term
(in years)

   Aggregate intrinsic value 
                 
Outstanding as of January 1, 2020   381,910   $14.62    1.64   $
-
 
Granted   35,100    7.60           
Exercised   
-
    
-
           
Expired and forfeited   (111,171)   13.52           
                     
Outstanding as of December 31, 2020   305,839    14.21    1.33    98 
                     
Vested and expected to vest at December 31, 2020   305,839    14.21    1.33    98 
                     
Exercisable as of December 31, 2020   247,741    14.44    0.93    14 

 

Schedule of stock options under the 2013 share option plan
   

Options outstanding

at December 31, 2020

  

Options exercisable

at December 31, 2020

 
Exercise price   Number outstanding   Weighted average exercise price   Weighted average remaining contractual life   Number exercisable   Weighted average exercise price   Weighted average remaining contractual life 
$       $   In years       $   In years 
                          
7.6    35,100    7.6    4.53    4,875    7.6    4.53 
11.29-12.65    155,350    11.89    0.53    155,350    11.89    0.53 
18.9-19.85    115,389    19.34    1.44    87,516    19.34    1.43 
                                
     305,839              247,741           

 

Schedule of RSUs activity
   Number of RSUs  

Weighted average remaining contractual term

(in years)

   Aggregate intrinsic value 
             
Outstanding as of January 1, 2020   448,813    1.53   $3,824 
Granted   340,000           
Vested   (145,303)          
Cancelled   (92,335)          
                
Outstanding as of December 31, 2020   551,175    1.51   $5,732 

 

Schedule of department allocation of share-based compensation charges
   Year ended December 31, 
   2020(*)   2019(*)   2018(*) 
             
Cost of revenues  $106   $204   $112 
Research and development, net   879    729    808 
Sales and marketing   536    638    698 
General and administrative   648    657    503 
                
   $2,169   $2,228   $2,121